Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 18, 2008 - Issue 8
Submit an article Journal homepage
121
Views
20
CrossRef citations to date
0
Altmetric
Review

EGFR-targeting agents in oncology

Sonia Garofalo Both authors have contributed equally to the manuscript.; University of Naples Federico II, Clinical Unit and Laboratory of Molecular Cancer Therapy, Department of Molecular and Clinical Endocrinology and Oncology, Via S. Pansini 5, 80131 Naples, Italy
,
Roberta Rosa Both authors have contributed equally to the manuscript.; University of Naples Federico II, Clinical Unit and Laboratory of Molecular Cancer Therapy, Department of Molecular and Clinical Endocrinology and Oncology, Via S. Pansini 5, 80131 Naples, Italy
,
Roberto Bianco Assistant Professor of Medical Oncology University of Naples Federico II, Clinical Unit and Laboratory of Molecular Cancer Therapy, Department of Molecular and Clinical Endocrinology and Oncology, Via S. Pansini 5, 80131 Naples, Italy +39 081 7463661; +39 081 2203147; [email protected]
, MD PhD &
Giampaolo Tortora University of Naples Federico II, Clinical Unit and Laboratory of Molecular Cancer Therapy, Department of Molecular and Clinical Endocrinology and Oncology, Via S. Pansini 5, 80131 Naples, Italy
, MD PhD
Pages 889-901 | Published online: 04 Aug 2008
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Background: The ‘targeted therapy’ has been defined as an innovative therapy designed to interfere with molecular targets playing a critical role in tumour growth or progression. The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor mediating the effect of growth factors both in physiological and pathological conditions; aberrations in the EGFR may result in the development of a tumour phenotype. Objective: To summarise the current state of the development of anti-EGFR drugs. Methods: Patent literature and preclinical/clinical studies about EGFR inhibitors are analysed. Conclusion: Some monoclonal antibodies and small-molecule tyrosine kinase inhibitors have been approved in several countries for the treatment of various human cancer types; moreover, more than ten EGFR-targeting agents are actually in advanced clinical development.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.
Source: Oxford University Press (OUP)
Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinone analogues.
Source: Taylor & Francis
Molecular and biological properties of vascular endothelial growth factor.
Source: Springer Science and Business Media LLC
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib
Source: Elsevier BV
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Source: American Association for Cancer Research (AACR)
Epidermal growth factor receptor biology (IMC-C225)
Source: Ovid Technologies (Wolters Kluwer Health)
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Source: Proceedings of the National Academy of Sciences
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Source: American Association for Cancer Research (AACR)
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
Source: Elsevier BV
Inhibition of Tumor Growth by Ribozyme-Mediated Suppression of Aberrant Epidermal Growth Factor Receptor Gene Expression
Source: Oxford University Press (OUP)
Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).
Source: Informa UK Limited
The activation of Akt/PKB signaling pathway and cell survival
Source: Wiley
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
Source: Elsevier BV
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Source: Public Library of Science (PLoS)
Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab
Source: Informa UK Limited
The role of EGF-related peptides in tumor growth.
Source: Frontiers in Bioscience
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
Source: American Society of Clinical Oncology (ASCO)
Active and inactive conformations of the epidermal growth factor receptor
Source: Portland Press Ltd.
Activation of the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathway by Conventional, Novel, and Atypical Protein Kinase C Isotypes
Source: American Society for Microbiology
Stat proteins and oncogenesis
Source: American Society for Clinical Investigation
Cetuximab for Esophageal Squamous Cell Carcinoma
Source: Wiley
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Source: American Society of Clinical Oncology (ASCO)
Synthesis, characterization of novel quinoline-2-carboxamide based chalcone derivatives and their molecular docking, photochemical studies
Source: Taylor & Francis
Phospholipase C-γ: diverse roles in receptor-mediated calcium signaling
Source: Elsevier BV
Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.
Source: Springer Science and Business Media LLC
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
Source: Elsevier BV
EGF mutant receptor vIII as a molecular target in cancer therapy.
Source: Bioscientifica
EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes
Source: American Physiological Society
MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression
Source: Elsevier BV
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Source: Oxford University Press (OUP)
EGF receptor signaling inhibits keratinocyte apoptosis: Evidence for mediation by Bcl-XL
Source: Springer Science and Business Media LLC
ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation.
Source: Elsevier BV
Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo
Source: American Association for Cancer Research (AACR)
The EGF Receptor System as a Target for Antitumor Therapy
Source: Informa UK Limited
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Source: Massachusetts Medical Society
Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer
Source: Springer Berlin Heidelberg
Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
Source: Ovid Technologies (Wolters Kluwer Health)
Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
Source: Wiley
Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological Activities
Source: Elsevier BV
Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Source: Wiley
Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α
Source: Elsevier BV
Rational bases for the development of EGFR inhibitors for cancer treatment.
Source: Elsevier BV
First-Line Use of Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer
Source: Elsevier BV
Genetic pathways to glioblastomas.
Source: Wiley
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.
Source: Elsevier BV
Lapatinib in breast cancer
Source: Elsevier BV
p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Source: American Association for Cancer Research (AACR)
Oncogenic PI3K and its role in cancer.
Source: Ovid Technologies (Wolters Kluwer Health)

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.